Erytech Pharma (NASDAQ:ERYP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The firm currently has a $12.00 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 18.81% from the stock’s current price.

According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “

Separately, Cowen restated a “buy” rating on shares of Erytech Pharma in a research report on Monday, June 25th.

Shares of ERYP stock opened at $10.10 on Monday. The stock has a market capitalization of $189.21 million and a P/E ratio of -3.03. Erytech Pharma has a 52-week low of $9.72 and a 52-week high of $30.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.50 and a current ratio of 16.52.

An institutional investor recently bought a new position in Erytech Pharma stock. Millennium Management LLC purchased a new stake in Erytech Pharma SA (NASDAQ:ERYP) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 43,567 shares of the company’s stock, valued at approximately $959,000. Millennium Management LLC owned 0.25% of Erytech Pharma as of its most recent SEC filing. 25.65% of the stock is currently owned by hedge funds and other institutional investors.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

Read More: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with's FREE daily email newsletter.